Literature DB >> 6975478

Synergistic interaction between 1-beta-D-arabinofuranosylcytosine, thymidine, and hydroxyurea against human B cells and leukemic blasts in vitro.

J A Streifel, S B Howell.   

Abstract

Isobologram analysis was used to examine the interaction between 1-beta-D-arabinofuranosylcytosine (Ara-C), thymidine (dThd), and hydroxyurea. All three pairs of drugs, as well as the triple combination, were synergistic against a human B cell line in vitro across a broad range of concentrations. Synergy was associated with an increase in the Ara-C nucleotide pool and Ara-C triphosphate concentration. dThd increased, and hydroxyurea decreased, the incorporation of Ara-C into trichloroacetic acid-insoluble macromolecules per unit time. Hydroxyurea was more effective than dThd at equimolar concentrations in increasing the acid-soluble Ara-C pool. Maximal stimulation of Ara-C triphosphate formation by dThd occurred at 1 mM and was associated with reduction of the deoxycytidine triphosphate pool to 31% of control. At the same concentration, hydroxyurea increased Ara-C triphosphate formation to a greater extent but increased deoxycytidine triphosphate to 116% of control. When tested at clinically achievable concentrations on blasts from patients with acute leukemia, hydroxyurea increased the Ara-C nucleotide pool in all six cases studied, whereas dThd decreased the Ara-C nucleotide pool. These results indicate that in SB cells dThd and hydroxyurea work by different mechanisms to augment the Ara-C nucleotide pool and that hydroxyurea may be more effective than dThd as a modulator of Ara-C activity in patients with acute leukemia.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6975478      PMCID: PMC320347          DOI: 10.1073/pnas.78.8.5132

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  60 in total

1.  The metabolism of cytosine arabinoside as a predictive test for clinical response to the drug in acute myeloid leukaemia.

Authors:  J F Smyth; A B Robins; C L Leese
Journal:  Eur J Cancer       Date:  1976-07       Impact factor: 9.162

2.  Metabolism and intracellular retention of 1-beta-D-arabinofuranosylcytosine as predictors of response of animal tumors.

Authors:  Y M Rustum
Journal:  Cancer Res       Date:  1978-03       Impact factor: 12.701

3.  Inhibition of growth rate and deoxynucleoside triphosphate concentrations in cultured leukemia L1210 cells.

Authors:  J K Lowe; G B Grindey
Journal:  Mol Pharmacol       Date:  1976-01       Impact factor: 4.436

4.  Clinical, biological, and biochemical effect of pyrazofurin.

Authors:  E C Cadman; D E Dix; R E Handschumacher
Journal:  Cancer Res       Date:  1978-03       Impact factor: 12.701

Review 5.  Metabolism of 1-beta-D-arabinofuranosylcytosine in human leukemic cells.

Authors:  T C Chou; Z Arlin; B D Clarkson; F S Phillips
Journal:  Cancer Res       Date:  1977-10       Impact factor: 12.701

Review 6.  Synergy, additivism and antagonism in immunosuppression. A critical review.

Authors:  M C Berenbaum
Journal:  Clin Exp Immunol       Date:  1977-04       Impact factor: 4.330

7.  Toxicity of combinations of arabinosylcytosine and 3-deazauridine toward neoplastic cells in culture.

Authors:  C Mills-Yamamoto; G J Lauzon; A R Paterson
Journal:  Biochem Pharmacol       Date:  1978-01-15       Impact factor: 5.858

8.  Deoxyribonucleoside triphosphate pools and differential thymidine sensitivities of cultured mouse lymphoma and myeloma cells.

Authors:  E C Reynolds; A W Harris; L R Finch
Journal:  Biochim Biophys Acta       Date:  1979-01-26

Review 9.  The lethality of aranucleotides.

Authors:  S S Cohen
Journal:  Med Biol       Date:  1976-12

10.  Treatment of acute leukemia in adults.

Authors:  B D Clarkson; M D Dowling; T S Gee; I B Cunningham; J H Burchenal
Journal:  Cancer       Date:  1975-08       Impact factor: 6.860

View more
  6 in total

Review 1.  A comparison of the effects of cytosine arabinoside and beta-lactams on DNA synthesis and cellular proliferation.

Authors:  R J Fram
Journal:  Cell Biol Toxicol       Date:  1986-12       Impact factor: 6.691

2.  Interrelationships of protein and DNA syntheses during replication of mammalian cells.

Authors:  E Sariban; R S Wu; L C Erickson; W M Bonner
Journal:  Mol Cell Biol       Date:  1985-06       Impact factor: 4.272

3.  Cisplatin preceded by concurrent cytarabine and hydroxyurea: a pilot study based on an in vitro model.

Authors:  K S Albain; L J Swinnen; L C Erickson; P J Stiff; R I Fisher
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

4.  A phase II study of cisplatin preceded by a 12-h continuous infusion of concurrent hydroxyurea and cytosine arabinoside (Ara-C) for adult patients with malignant gliomas (Southwest Oncology Group S9149).

Authors:  Lode J Swinnen; Cathryn Rankin; Hetty Carraway; Kathy S Albain; Jeannette J Townsend; George Thomas Budd; Julie A Kish; Saul E Rivkin; Deborah T Blumenthal
Journal:  J Neurooncol       Date:  2007-11-16       Impact factor: 4.130

Review 5.  Thymidine as an anticancer agent, alone or in combination. A biochemical appraisal.

Authors:  P H Ellims
Journal:  Cancer Chemother Pharmacol       Date:  1982-12       Impact factor: 3.333

6.  Ribonucleotide reductase inhibitors suppress SAMHD1 ara-CTPase activity enhancing cytarabine efficacy.

Authors:  Sean G Rudd; Nikolaos Tsesmetzis; Kumar Sanjiv; Cynthia Bj Paulin; Lakshmi Sandhow; Juliane Kutzner; Ida Hed Myrberg; Sarah S Bunten; Hanna Axelsson; Si Min Zhang; Azita Rasti; Petri Mäkelä; Si'Ana A Coggins; Sijia Tao; Sharda Suman; Rui M Branca; Georgios Mermelekas; Elisée Wiita; Sun Lee; Julian Walfridsson; Raymond F Schinazi; Baek Kim; Janne Lehtiö; Georgios Z Rassidakis; Katja Pokrovskaja Tamm; Ulrika Warpman-Berglund; Mats Heyman; Dan Grandér; Sören Lehmann; Thomas Lundbäck; Hong Qian; Jan-Inge Henter; Torsten Schaller; Thomas Helleday; Nikolas Herold
Journal:  EMBO Mol Med       Date:  2020-01-17       Impact factor: 12.137

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.